Phenomix Corporation Announces PHX1149 Phase 2b Clinical Trial Results for Type 2 Diabetes
5/19/2008 10:04:08 AM
SAN DIEGO--(BUSINESS WIRE)--Phenomix Corporation announced today that PHX1149, a dipeptidyl peptidase-4 (DPP-4) inhibitor, demonstrated positive results in a Phase 2b clinical trial for the treatment of Type 2 diabetes.
|